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The c-Myc Oncoprotein Interacts with Bcr
region between the PH domain and the C2 domain (Fig-Gwendolyn M. Mahon,1 Yan Wang,2
Malgorzata Korus,1 Elena Kostenko,1 Li Cheng,1 ure 1A).
In order to identify the region of c-Myc that interactsTong Sun,2 Ralph B. Arlinghaus,2
and Ian P. Whitehead1,* with Bcr, a panel of derivatives was constructed that
contained different fragments of the c-Myc protein (Fig-1Department of Microbiology
and Molecular Genetics ure 1B), and each was tested for its ability to interact
with full-length Bcr. The smallest fragment of c-Myc thatUMDNJ-New Jersey Medical School
P.O. Box 1709 we have identified that retains its ability to interact with
the full-length Bcr clone consists of the carboxy-termi-225 Warren Street
Newark, New Jersey 07101-1709 nal B/HLH/Z domain.
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The University of Texas M.D. Anderson
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Next, we wished to determine whether Bcr interacts with
full-length c-Myc, and whether this interaction can be
recapitulated in mammalian cells. To address theseSummary
questions, we coexpressed full-length c-Myc and hem-
agglutinin-tagged (HA) full-length Bcr in COS-7 cells andBcr is a multifunctional protein that is the fusion part-
performed coimmunoprecipitations (Figure 2A) with ei-ner for Abl (p210 Bcr-Abl) in Philadelphia chromosome
ther anti-HA (F7, Santa Cruz) or anti-Myc (C-33, Santapositive leukemias. We have identified c-Myc as a
Cruz) monoclonal antibodies. In either case, we werebinding partner for Bcr in both yeast and mammalian
able to detect an interaction between full-length Bcr andcells. We are also able to observe interactions between
c-Myc. To confirm that c-Myc interacts with the carboxylnatively expressed c-Myc and Bcr in leukemic cell
terminus of Bcr, we then repeated the coimmunoprecipi-lines. Although Bcr and Max have overlapping binding
tation with two smaller nonoverlapping fragments of Bcrsites on c-Myc, Bcr cannot interact with Max, or with
(Figure 2B). Consistent with what we observed in yeast,the c-Myc•Max heterodimer. Bcr expression blocks
we were able to precipitate c-Myc with a Bcr fragmentactivation of c-Myc-responsive genes, as well as the
that encoded the carboxyl terminus of Bcr (residuestransformed phenotype induced by coexpression of
871–1271), but not a fragment that encodes the aminoc-Myc and H-Ras, and this finding suggests that one
terminus (residues 1–871). To further confirm that thefunction of Bcr is to limit the activity of c-Myc. How-
interaction between Bcr and c-Myc is direct, we purifiedever, Bcr does not block c-Myc function by preventing
Baculovirus-expressed, full-length FLAG-tagged c-Mycits nuclear localization. Interestingly, increased Bcr
from insect Sf9 cells and performed an in vitro affinitydosage in COS-7 and K-562 cells correlates with a
precipitation with bacterially expressed GST-Bcr(871–reduction in c-Myc protein levels, suggesting that Bcr
1271). A Western blot with an anti-Myc monoclonal anti-may in fact be limiting c-Myc activity by regulating
body (C-33, Santa Cruz) demonstrated an interactionits stability. These data indicate that Bcr is a novel
between c-Myc and GST-Bcr(871–1271), but not be-regulator of c-Myc function whose disrupted expres-
tween c-Myc and GST alone (Figure 2C).sion may contribute to the high level of c-Myc protein
Since the putative Bcr binding site for c-Myc is presentthat is observed in Bcr-Abl transformed cells.
within p210 Bcr-Abl, c-Myc and p210 Bcr-Abl may also
interact. However, in cotransfection experiments, we
Results and Discussion were unable to coimmunoprecipitate p210 Bcr-Abl with
an anti-Myc monoclonal antibody (C-33, Santa Cruz),
p160 Bcr Interacts with c-Myc in Yeast despite the fact that we were able to coimmunprecipi-
In order to identify new binding partners for p160 Bcr, tate p160 Bcr under the same experimental conditions
a yeast two-hybrid screen was performed. Multiple inde- (Figure 2D).
pendent copies of four structurally unrelated clones To determine whether the interaction between full-
were identified that interacted with a full-length p160 Bcr length Bcr and c-Myc occurs in a more physiologically
bait. One of these clones encodes a carboxy-terminal relevant context, the association between natively ex-
fragment of c-Myc (residues 103–439) that includes the pressed proteins was also examined in K-562 and HL-
complete Myc box II sequences as well as an intact 60 cells (Figure 2E). K-562 is a human myeloid cell line
basic/helix-loop-helix/leucine zipper (B/HLH/Z) domain. that was isolated from a patient with chronic myeloge-
Our efforts to more precisely define the binding site for nous leukemia (CML) and is positive for p210 Bcr-Abl.
c-Myc with an extended panel of Bcr baits revealed an HL-60 cells are a leukemic cell line of myeloid origin that
interaction between c-Myc and a Bcr fragment con- does not contain Bcr-Abl but expresses high levels of
taining residues 871–910 that encompasses the small c-Myc. In both instances, we were able to coimmuno-
precipitate p160 Bcr with a monoclonal antibody spe-
cific for c-Myc (C-33; Santa Cruz; Figure 2D, top panel).*Correspondence: whiteip@umdnj.edu
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Figure 1. Yeast Two-Hybrid Assays Identify c-Myc as a Binding Partner for p160 Bcr
(A) Mapping of the c-Myc binding site within p160 Bcr. The domain structure of the full-length Bcr protein is illustrated in the upper line (O,
oligomerization domain; kinase, serine/threonine kinase domain; DH, Dbl homology domain; PH, pleckstrin homology domain; C2, calcium
binding domain; GAP, GTPase activating protein domain), and the lines below indicate the regions of the protein included in predicted
translation products of the various cDNA derivatives. In the lower panels, yeast colonies that grew on plates lacking leucine and tryptophan
(Leu/Trp) were examined for growth on histidine-deficient plates (Leu/Trp/His). Growth in the absence of leucine indicates the presence of
pGAD containing residues 102–439 of c-Myc, while growth in the absence of tryptophan indicates the presence of pGBT9 containing the
indicated derivatives of Bcr. Interactions between proteins are demonstrated by the ability to activate the HIS3 reporter gene.
(B) Full-length Bcr binds to the carboxy-terminal B/HLH/Z domain of c-Myc. The domain structure of the full-length c-Myc protein is illustrated
in the upper line (I and II, Myc boxes I and II; b, basic domain; HLH, helix-loop-helix fold; Z, leucine zipper), and the lines below indicate the
regions of the protein included in predicted translation products of the various cDNA derivatives. In the lower panels, interactions between
full-length p160 Bcr and the indicated derivatives of c-Myc were determined as described above.
The specificity of this interaction was confirmed by our Bcr Limits c-Myc Transactivation
and Transforming Activityfailure to precipitate Bcr with an irrelevant HA antibody
(F7; Santa Cruz; second panel from top). The c-Myc Since c-Myc has been best characterized as a transcrip-
tional regulator, we wondered whether the interactionantibody did not coimmunoprecipitate p210 Bcr-Abl
from K-562 cells, which is consistent with what we ob- with Bcr would influence c-Myc-mediated transcrip-
tional activity. Using in vitro oligonucleotide bindingserved in our overexpression experiments (see Fig-
ure 2D). assays, it has been shown that a c-Myc•Max hetero-
Figure 2. Full-Length c-Myc Interacts with p160 Bcr in Mammalian Cells
(A–E) Prec. indicates the antibody used in immunoprecipitations, and Det. indicates the antibody used in a Western blot to detect an interaction.
(A, B, and D) COS-7 cells were cotransfected with the indicated combinations of plasmids (vector, pAX142; Bcr, pAX142-bcr(1–1271); Myc,
pAX142-myc; 1–871, pAX142-bcr(1–871); 871–1271, pAX142-bcr(871–1271); Bcr-Abl, pAX142-bcr-abl). Lysates were collected at 48 hr and
were examined by Western blot for expression of the appropriate plasmids (Tot. lysate). Immunoprecipitations were then performed with the
indicated antibodies to detect an interaction. (A) Full-length c-Myc interacts with p160 Bcr. (B) c-Myc interacts with the carboxyl terminus of
Bcr. (C) Full-length FLAG-myc protein interacts with GST-Bcr(871–1271) in an in vitro affinity precipitation assay. Baculovirus-expressed FLAG-
myc protein was purified from Sf9 cells, and then incubated with bacterially purified sepharose-linked GST or GST-Bcr(871–1271). The beads
were then washed, and an interaction was demonstrated by Western blot with an anti-Myc antibody. (D) Full-length c-Myc does not interact
with p210 Bcr-Abl. (E) Natively expressed Bcr interacts with natively expressed c-Myc in hematopoietic cell lines. Lysates were collected
from K-562 and HL-60 cells and were examined for expression of c-Myc and p160 Bcr (lower two panels). Lysates were then precipitated
with either anti-Myc (upper panel) or an irrelevant anti-HA (second panel) antibody, and interactions were demonstrated by Western blot with
an anti-Bcr antibody that recognizes the amino terminus of both p160 Bcr and p210 Bcr-Abl (upper panel).
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Figure 3. Bcr Limits c-Myc Transactivation and Transforming Activity
(A) p160 Bcr blocks activation of c-Myc response elements by c-Myc. COS-7 cells were cotransfected (3 g of each plasmid) with the indicated
combinations of pAX142 (vector), pAX142-bcr(1–1271), or pAX142-myc, along with 2.5 g pMyc-TA-luc (Clontech),and 500 ng pCMVnlac as
an internal control for transfection efficiency and/or growth inhibition. Luciferase assays were performed as described in the Experimental
Procedures. Data shown are representative of three independent experiments performed on triplicate plates. Error bars indicate standard
deviations.
(B) Western blot showing stable expression of p160 Bcr in mycER (Rat1a) cells.
(C and D) p160 Bcr blocks transcriptional activation of cyclin D2 (CD2) by c-Myc. mycER cells that express either vector or Bcr were serum
starved (0.25% charcoal stripped FCS) for 24 hr, and then c-Myc was induced with 2 M -estradiol (estrogen). (C) Lysates were collected
at 1 hr and 3 hr and were examined by Western blot for expression of CD2 and -actin. (D) Total mRNA was collected at 0, 0.5, and 1.0 hr
and was examined by Northern blot for expression of CD2 and GAPDH.
(E) Bcr blocks c-Myc focus formation in NIH 3T3 cells. NIH 3T3 cells were cotransfected with combinations of pAX142 (vector) or pAX142
that encodes the indicated proteins (Myc, pAX142-myc [3 g]; Bcr, pAX142-bcr(1–1271) [3 g]; Ras, pAX142-ras(12V) [100 ng]). Primary focus
formation assays were performed as described in the Experimental Procedures, and foci were counted at 14 days. Data shown are the average
of three assays performed on duplicate plates.
dimer is capable of recognizing the core sequence transforming activity of c-Myc in NIH 3T3 cells. Although
c-Myc is not transforming when expressed alone in NIHCA(C/T)GTG, termed the E-box [1–3]. c-Myc is capable
of transactivating artificial constructs that contain tan- 3T3 cells, it will cooperate with a constitutively activated
mutant of Ras (Ras(12V)) in a primary focus formationdem E-box sequences in the promoters of reporter
genes [4]. In our analysis, we utilized a c-Myc-respon- assay (Figure 3E, [6, 7]). Coexpression of full-length Bcr
with c-Myc and Ras(12V) completely blocked the contri-sive reporter plasmid that contains the gene for lucifer-
ase fused at the amino terminus to E-box elements bution of c-Myc to Ras(12V) transformation. When ex-
pressed in the absence of c-Myc, Bcr did not inhibit(pMyc-TA-luc [Clontech]). When we expressed c-Myc
alone with this reporter, we observed a 4-fold increase Ras(12V) transformation or transformation by an unre-
lated oncogene (Dbl, not shown), and this finding againin luciferase activity (Figure 3A), which is consistent with
what has been observed previously [4]. Activation of the suggests that Bcr acts by specifically inhibiting c-Myc
function.reporter was blocked by coexpression with full-length
Bcr, suggesting that Bcr can limit c-Myc transcriptional
activity. c-Myc Protein Levels Are Sensitive to Bcr Dosage
Next, we wished to investigate the mechanism throughTo further examine the consequences of Bcr expres-
sion on c-Myc transcriptional activity, we examined the which Bcr can limit c-Myc function. Although c-Myc
does not form homodimers in vivo, heterodimers con-expression of an endogenous c-Myc target gene in the
presence of Bcr. For this analysis, we established sisting of c-Myc and its protein partner Max recognize
specific DNA sequences contained within the promotersmycER (Rat1a) cell lines that were stably transfected
with either vector or full-length Bcr (Figure 3B). It has of multiple cellular genes [8]. Since the binding of Max
to c-Myc occurs through their respective B/HLH/Z do-been shown previously that cyclin D2 expression is ele-
vated in response to c-Myc induction in this cell type [5], mains, we wondered whether Bcr inhibits c-Myc by in-
terfering with this interaction. Although we were readilyand, consistent with this, we observed elevated levels of
cyclin D2 protein (Figure 3C, 3.7-fold) and mRNA (Figure able to detect an interaction between overexpressed
c-Myc and either endogenous or overexpressed Max in3D) in our vector-expressing cells when c-Myc was in-
duced with estrogen. Stable expression of full-length COS-7 cells (Figure 4A), we were unable to detect an
interaction between Bcr and Max (Figure 4B). This sug-Bcr blocks cyclin D2 induction, again suggesting that
Bcr can block transactivation of target genes by c-Myc. gests that the interaction between Bcr and c-Myc is
specific and does not extend to all B/HLH/Z proteins.To determine whether Bcr can influence cellular activi-
ties that accompany deregulated c-Myc expression, we When we performed a triple transfection with Bcr, Max,
and c-Myc (Figure 4C), we were unable to detect analso examined the effects of Bcr expression on the
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Figure 4. c-Myc Protein Levels Are Sensitive to Bcr Dosage
(A–C) Bcr does not bind Max or the c-Myc•Max heterodimer. COS-7 cells were cotransfected with the indicated combination of plasmids.
Vector is empty pAX142, while Myc, Max, and Bcr are pAX142-myc, pAX142-max, and pAX142-bcr(1–1271), respectively. Immunoprecipitations
were performed as described in Figure 2.
(D) p160 Bcr does not prevent nuclear accumulation of c-Myc. COS-7 cells were cotransfected with the indicated combinations of plasmids.
At 48 hr, lysates were collected and separated into nuclear (N) and cytoplasmic (C) fractions as described in the Experimental Procedures.
A total of 25% of the nuclear lysates and 10% of the cytoplasmic lysates were compared for each condition. Protein expression was determined
by Western blot with the indicated antibodies. The relative amounts of protein in matched nuclear and cytoplasmic fractions (%) were
determined with a PhosphorImager (Molecular Dynamics).
(E) c-Myc protein levels are sensitive to Bcr dosage in COS-7 cells. COS-7 cells were cotransfected with the same combination of plasmids
as in (D), except pAX142-dbs(HA6) was also included as a control for transfection efficiency. Lysates were collected at 48 hr, and protein
expression was determined by Western blot with the indicated antibodies.
(F) Increased p160 Bcr dosage in K-562 cells is associated with decreased levels of c-Myc. Lysates were collected from the K12 K-562 Tet-
off clone at different time points after removal of the Bcr tet transcription block. Lysates from the different time points were analyzed by
Western blot for expression of p160 Bcr, c-Myc, and -actin (as an internal control).
(G) Control K-562 cells were maintained on tetracycline for 14 days, and then lysates were collected after Tet removal for the indicated time
points. Lysates were examined by Western blot for expression of c-Myc or -actin (as an internal control). Control K-562 cells were maintained
on tetracycline for 14 days, and then lysates were collected after Tet removal for the indicated time points. Lysates were examined by Western
blot for expression of c-Myc or -actin.
interaction between c-Myc and Bcr, even though we are of Bcr, and this effect was even more apparent when
we examined whole-cell lysates (Figure 4E). This reduc-able to detect the interaction in the absence of overex-
pressed Max (compare lanes 2 and 3). Collectively, these tion in protein levels could not be attributed to cotrans-
fection efficiency since an internal control for transfec-observations suggest that the binding of c-Myc to Max
and Bcr may be mutually exclusive events and that Bcr tion efficiency (Dbs) was expressed equally in all
conditions (Figure 4E). Thus, although Bcr does not ap-cannot efficiently compete with Max for binding to
c-Myc. pear to modify the cellular partitioning of c-Myc, it may
have an effect on the overall levels of c-Myc expression.To determine whether Bcr may block c-Myc transcrip-
tional activity by preventing its translocation to the nu- Since c-Myc protein levels appear to be responsive
to Bcr dosage in COS-7 cells, we wondered whethercleus, we examined the nuclear and cytoplasmic frac-
tions of COS-7 cells that coexpress Bcr and c-Myc Bcr dosage may also influence the steady-state levels
of c-Myc that are present in Bcr-Abl-positive cell lines.(Figure 4D). Surprisingly, we were able to detect high
levels of Bcr in the nuclear fraction of COS-7 cells even To address this possibility, we made use of a K-562 cell
line that contains a conditional allele of full-length Bcr.in the absence of c-Myc expression (upper panel). This
could not be attributed to cross-contamination of the Our previous studies established an inducible BCR gene
expression system in clones of K-562 cells containingfractions since the nuclear protein lamin and the cyto-
plasmic protein Rac1 were efficiently partitioned in the a tetracycline(Tet)-off BCR gene [9]. The Bcr Tet-off sys-
tem is characterized by strong induction of p160 Bcrsame lysates (lower 2 panels). When coexpressed with
c-Myc, we consistently observed a much higher fraction after removal of tetracycline from the culture medium
(Figure 4F, upper panel). Release from the Tet block inof Bcr in the nucleus (92% versus 61%), suggesting that
c-Myc can contribute to the nuclear localization of Bcr. the Tet-off clone of K-562 cells induced expression of
Bcr that is readily detectable by day 10 and reaches ac-Myc was also detected in both the nuclear and cyto-
plasmic fractions, and the relative concentrations did maximum by day 21. Examination of the same lysates
revealed a dramatic reduction in levels of c-Myc thatnot change appreciably in response to Bcr expression.
However, the overall levels of both nuclear and cyto- was first detectable by day 2 and continued through
day 21 (Figure 4F, middle panel). This reduction wasplasmic c-Myc were consistently lower in the presence
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cycle progression and sequestration of p27. EMBO J. 18, 5321–verified in three independent release experiments con-
5333.ducted on two independent cell clones (data not shown).
6. Land, H., Parada, L.F., and Weinberg, R.A. (1983). TumorigenicThe reduction could not be attributed to nonspecific
conversion of primary embryo fibroblasts requires at least two
reductions in levels of protein expression since -actin cooperating oncogenes. Nature 304, 596–602.
levels remained constant throughout the course of the 7. Ruley, H.E. (1990). Transforming collaborations between ras and
nuclear oncogenes. Cancer Cells 2, 258–268.experiment (Figure 4F, lower panel). In addition, alter-
8. Grandori, C., Cowley, S.M., James, L.P., and Eisenman, R.N.ations in c-Myc levels could not be attributed to a non-
(2000). The Myc/Max/Mad network and the transcriptional con-specific activity associated with tetracycline withdrawal
trol of cell behavior. Annu. Rev. Cell Dev. Biol. 16, 653–699.since control K-562 cells that had been maintained on
9. Lin, F., Monaco, G., Sun, T., Liu, J., Lin, H., Stephens, C., Bel-
tetracycline for 14 days exhibited no changes in c-Myc mont, J., and Arlinghaus, R.B. (2001). BCR gene expression
levels upon tetracycline withdrawal (Figure 4G, upper blocks Bcr-Abl induced pathogenicity in a mouse model. Onco-
gene 20, 1873–1881.panel). These observations suggest that c-Myc levels
10. Nesbit, C.E., Tersak, J.M., and Prochownik, E.V. (1999). MYCare sensitive to Bcr dosage in K-562 cells and are consis-
oncogenes and human neoplastic disease. Oncogene 18, 3004–tent with the lower levels of c-Myc expression that we
3016.observed in COS-7 cells when Bcr is coexpressed (Fig-
11. Sawyers, C.L. (1993). The role of myc in transformation by BCR-
ure 4E). ABL. Leuk. Lymphoma 11, 45–46.
12. Sawyers, C.L., Callahan, W., and Witte, O.N. (1992). Dominant
negative MYC blocks transformation by ABL oncogenes. CellConclusions
70, 901–910.Elevation in the levels of c-Myc is a widespread phenom-
enon in a large variety of human tumors, and there is a
strong feeling that the deregulated expression of c-Myc
contributes substantively to the progression of many
malignancies [10]. Not surprisingly, c-Myc is also
thought to play an important role in the progression of
CML. Levels of c-Myc are elevated in Bcr-Abl trans-
formed cells [11], and dominant inhibitory derivatives of
c-Myc can effectively block Bcr-Abl transformation [12].
Our observation that c-Myc levels are responsive to Bcr
dosage in Bcr-Abl transformed cells suggests a direct
mechanism by which c-Myc protein levels may become
elevated in Bcr-Abl transformed cells. The contribution
of this activity to the transforming potential of Bcr-Abl,
particularly within the context of CML progression, is
currently under investigation.
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Supplementary Material including additional methodological details
is available at http://images.cellpress.com/supmat/supmatin.htm.
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